NCT00270647

Brief Summary

The use of vitamin E, vitamin C, beta carotene, and/or multivitamins may keep cancer, cardiovascular disease, eye diseases, or cognitive decline from occurring. This randomized clinical trial studied vitamin E, vitamin C, beta carotene, and/or multivitamins to see how well they work compared with placebos in preventing cancer, cardiovascular disease, eye disease, and cognitive decline in male doctors aged 50 years and older.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14,641

participants targeted

Target at P75+ for not_applicable cancer

Timeline
Completed

Started Jul 1997

Longer than P75 for not_applicable cancer

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 1997

Completed
8.5 years until next milestone

First Submitted

Initial submission to the registry

December 27, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 28, 2005

Completed
5.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2011

Completed
Last Updated

February 28, 2018

Status Verified

February 1, 2018

Enrollment Period

13.9 years

First QC Date

December 27, 2005

Last Update Submit

February 26, 2018

Conditions

Keywords

cancerprostate cancercolorectal cancercardiovascular diseaseeye diseasecognitive decline

Outcome Measures

Primary Outcomes (3)

  • Prostate cancer

    Ongoing

  • Total cancer

    Ongoing

  • Major cardiovascular events

    Ongoing

Secondary Outcomes (6)

  • Cataract

    Ongoing

  • Age-related macular degeneration

    Ongoing

  • Early cognitive decline

    Ongoing

  • Myocardial infarction

    Ongoing

  • Stroke

    Ongoing

  • +1 more secondary outcomes

Study Arms (4)

Vitamin E

EXPERIMENTAL

Active or placebo vitamin E

Dietary Supplement: Vitamin E

Vitamin C

EXPERIMENTAL

Active or placebo vitamin C

Dietary Supplement: Vitamin C

Multivitamin

EXPERIMENTAL

Active or placebo multivitamin

Dietary Supplement: Multivitamin

Beta-carotene

EXPERIMENTAL

Active or placebo beta-carotene

Dietary Supplement: Beta-carotene

Interventions

Vitamin EDIETARY_SUPPLEMENT

400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)

Vitamin E
Vitamin CDIETARY_SUPPLEMENT

500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)

Vitamin C
MultivitaminDIETARY_SUPPLEMENT

Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))

Multivitamin
Beta-caroteneDIETARY_SUPPLEMENT

50 mg Lurotin or placebo on alternate days (provided by BASF)

Beta-carotene

Eligibility Criteria

Age50 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • DISEASE CHARACTERISTICS:
  • Healthy male physicians practicing in the United States
  • Prior participation in the Physicians' Health Study I allowed
  • PATIENT CHARACTERISTICS:
  • Aged 50 years and over
  • No history of serious illness that would preclude study participation
  • No history of significant adverse events (e.g., rash or allergic reaction) attributed to study agents
  • PRIOR CONCURRENT THERAPY:
  • No other concurrent vitamin and/or multivitamin supplementation
  • No concurrent vitamin K-depleting anticoagulants (e.g., warfarin)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (13)

  • Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol. 2000 Feb;10(2):125-34. doi: 10.1016/s1047-2797(99)00042-3.

    PMID: 10691066BACKGROUND
  • Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Sesso HD, Buring JE. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2009 Jan 7;301(1):52-62. doi: 10.1001/jama.2008.862. Epub 2008 Dec 9.

  • Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2008 Nov 12;300(18):2123-33. doi: 10.1001/jama.2008.600. Epub 2008 Nov 9.

  • Christen WG, Glynn RJ, Sesso HD, Kurth T, Macfadyen J, Bubes V, Buring JE, Manson JE, Gaziano JM. Vitamins E and C and medical record-confirmed age-related macular degeneration in a randomized trial of male physicians. Ophthalmology. 2012 Aug;119(8):1642-9. doi: 10.1016/j.ophtha.2012.01.053. Epub 2012 Apr 13.

  • Christen WG, Glynn RJ, Sesso HD, Kurth T, MacFadyen J, Bubes V, Buring JE, Manson JE, Gaziano JM. Age-related cataract in a randomized trial of vitamins E and C in men. Arch Ophthalmol. 2010 Nov;128(11):1397-405. doi: 10.1001/archophthalmol.2010.266.

  • Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM. A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians' Health Study II. Arch Intern Med. 2007 Nov 12;167(20):2184-90. doi: 10.1001/archinte.167.20.2184.

  • Juraschek SP, Gaziano JM, Glynn RJ, Gomelskaya N, Bubes VY, Buring JE, Shmerling RH, Sesso HD. Effects of vitamin C supplementation on gout risk: results from the Physicians' Health Study II trial. Am J Clin Nutr. 2022 Sep 2;116(3):812-819. doi: 10.1093/ajcn/nqac140.

  • Rautiainen S, Gaziano JM, Christen WG, Bubes V, Kotler G, Glynn RJ, Manson JE, Buring JE, Sesso HD. Effect of Baseline Nutritional Status on Long-term Multivitamin Use and Cardiovascular Disease Risk: A Secondary Analysis of the Physicians' Health Study II Randomized Clinical Trial. JAMA Cardiol. 2017 Jun 1;2(6):617-625. doi: 10.1001/jamacardio.2017.0176.

  • Wang L, Sesso HD, Glynn RJ, Christen WG, Bubes V, Manson JE, Buring JE, Gaziano JM. Vitamin E and C supplementation and risk of cancer in men: posttrial follow-up in the Physicians' Health Study II randomized trial. Am J Clin Nutr. 2014 Sep;100(3):915-23. doi: 10.3945/ajcn.114.085480. Epub 2014 Jul 9.

  • Grodstein F, O'Brien J, Kang JH, Dushkes R, Cook NR, Okereke O, Manson JE, Glynn RJ, Buring JE, Gaziano M, Sesso HD. Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Ann Intern Med. 2013 Dec 17;159(12):806-14. doi: 10.7326/0003-4819-159-12-201312170-00006.

  • Christen WG, Glynn RJ, Manson JE, MacFadyen J, Bubes V, Schvartz M, Buring JE, Sesso HD, Gaziano JM. Effects of multivitamin supplement on cataract and age-related macular degeneration in a randomized trial of male physicians. Ophthalmology. 2014 Feb;121(2):525-34. doi: 10.1016/j.ophtha.2013.09.038. Epub 2013 Nov 20.

  • Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, Manson JE, Glynn RJ, Buring JE. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2012 Nov 14;308(18):1871-80. doi: 10.1001/jama.2012.14641.

  • Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, Manson JE, Glynn RJ, Buring JE, Gaziano JM. Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2012 Nov 7;308(17):1751-60. doi: 10.1001/jama.2012.14805.

MeSH Terms

Conditions

NeoplasmsProstatic NeoplasmsColorectal NeoplasmsCardiovascular DiseasesEye DiseasesCognitive Dysfunction

Interventions

Vitamin EAscorbic AcidGeritolbeta Carotene

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesCognition DisordersNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

BenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingSugar AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsHydroxy AcidsCarbohydratesCarotenoidsPolyenesAlkenesHydrocarbons, AcyclicHydrocarbonsCyclohexenesCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicTerpenesPigments, BiologicalBiological Factors

Study Officials

  • J. Michael Gaziano, MD, MPH

    Brigham and Women's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physician, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School

Study Record Dates

First Submitted

December 27, 2005

First Posted

December 28, 2005

Study Start

July 1, 1997

Primary Completion

June 1, 2011

Study Completion

June 1, 2011

Last Updated

February 28, 2018

Record last verified: 2018-02